lsc-webmaster

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer. Elraglusib (9-ING-41) is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is […]

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR  ELRAGLUSIB FOR TREATMENT OF PANCREATIC CANCER Read More »

 ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER 

 Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors  CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient

 ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER  Read More »

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER

Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER Read More »

Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.

Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results. Read More »

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER

Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met

ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER Read More »

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being

ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER Read More »